Outlook Therapeutics (OTLK) H.C. Wainwright 28th Annual Global Investment Conference summary

Key milestones and product positioning

• Achieved FDA approval for LYTENAVA, the first ophthalmic-specific, FDA-approved bevacizumab for wet AMD, addressing the need for a regulated, consistent, and safe supply chain in ophthalmology.

• LYTENAVA's label is based on robust clinical trials (NORSE TWO and NORSE EIGHT), allowing monthly dosing and providing a unique value proposition compared to off-label or repackaged alternatives.

• The product enables practices to access comprehensive support services, including hub services and co-pay assistance, which were previously unavailable with repackaged bevacizumab.

• The company is targeting a price point under $500 to ensure broad payer access, patient affordability, and competitive positioning against branded and biosimilar agents.

• U.S. market entry is informed by extensive research and segmentation, focusing on early adopters dissatisfied with repackaged products and leveraging lessons from slower European uptake.

Market strategy and segmentation

• The initial focus is on segments representing about a third of HCP targets and nearly half of potential volume, particularly those eager for an FDA-approved alternative.

• Early commercialization efforts will prioritize practices comfortable with temporary J-codes, with broader scaling anticipated after the permanent J-code becomes available in April 2027.

• The go-to-market approach is tailored to specific patient segments, including Medicare fee-for-service, commercial, and Medicare Advantage, each with distinct reimbursement and step-edit requirements.

• Practices using bevacizumab as a step therapy will be targeted, as these segments are likely to transition quickly to LYTENAVA for initial injections before moving to longer-acting agents.

• The company aims to penetrate 25–33% of accounts early, scaling to over a third to half of practices post-permanent J-code, with KPIs focused on coverage, conversion, and reorder rates.

Competitive landscape and pricing philosophy

• LYTENAVA is positioned as a backbone therapy in the anti-VEGF market, with over 2.2 million injections annually and a forecast to capture a significant share without displacing all repackaged products.

• The pricing strategy is built on broad access, practice dynamics, and patient affordability, with flexibility to adjust gross-to-net as needed for payer and provider contracting.

• Unlike biosimilars, LYTENAVA benefits from proprietary IP and a dedicated J-code, allowing for long-term ASP management and economic stability for practices.

• Biosimilars and branded competitors have not fundamentally shifted market dynamics, with adoption driven more by clinical and practice preferences than by aggressive pricing alone.

• Lessons from Europe highlight the importance of market-specific strategies, customer segmentation, and proactive engagement to drive adoption in the U.S.